

Matthew S Ellis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8978233/publications.pdf>

Version: 2024-02-01

38
papers

3,100
citations

304602

22
h-index

330025

37
g-index

38
all docs

38
docs citations

38
times ranked

2892
citing authors

#	ARTICLE	IF	CITATIONS
1	The Changing Face of Heroin Use in the United States. <i>JAMA Psychiatry</i> , 2014, 71, 821.	6.0	996
2	Effect of Abuse-Deterrent Formulation of OxyContin. <i>New England Journal of Medicine</i> , 2012, 367, 187-189.	13.9	285
3	Twin epidemics: The surging rise of methamphetamine use in chronic opioid users. <i>Drug and Alcohol Dependence</i> , 2018, 193, 14-20.	1.6	237
4	Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States. <i>JAMA Psychiatry</i> , 2015, 72, 424.	6.0	203
5	Polysubstance Use: A Broader Understanding of Substance Use During the Opioid Crisis. <i>American Journal of Public Health</i> , 2020, 110, 244-250.	1.5	178
6	Shifting Patterns of Prescription Opioid and Heroin Abuse in the United States. <i>New England Journal of Medicine</i> , 2015, 373, 1789-1790.	13.9	151
7	Increased use of heroin as an initiating opioid of abuse. <i>Addictive Behaviors</i> , 2017, 74, 63-66.	1.7	131
8	Multiple Determinants of Specific Modes of Prescription Opioid Diversion. <i>Journal of Drug Issues</i> , 2011, 41, 283-304.	0.6	109
9	The prescription opioid epidemic: a review of qualitative studies on the progression from initial use to abuse. <i>Dialogues in Clinical Neuroscience</i> , 2017, 19, 259-269.	1.8	93
10	Understanding the use of diverted buprenorphine. <i>Drug and Alcohol Dependence</i> , 2018, 193, 117-123.	1.6	92
11	Factors contributing to the rise of buprenorphine misuse: 2008–2013. <i>Drug and Alcohol Dependence</i> , 2014, 142, 98-104.	1.6	79
12	Patterns of prescription opioid abuse and comorbidity in an aging treatment population. <i>Journal of Substance Abuse Treatment</i> , 2012, 42, 87-94.	1.5	49
13	Increased use of heroin as an initiating opioid of abuse: Further considerations and policy implications. <i>Addictive Behaviors</i> , 2018, 87, 267-271.	1.7	48
14	Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. <i>Drug and Alcohol Dependence</i> , 2016, 168, 219-229.	1.6	44
15	Factors influencing the selection of hydrocodone and oxycodone as primary opioids in substance abusers seeking treatment in the United States. <i>Pain</i> , 2013, 154, 2639-2648.	2.0	37
16	Health Outcomes in Patients Using No-Prescription Online Pharmacies to Purchase Prescription Drugs. <i>Journal of Medical Internet Research</i> , 2012, 14, e174.	2.1	37
17	Understanding the demand side of the prescription opioid epidemic: Does the initial source of opioids matter?. <i>Drug and Alcohol Dependence</i> , 2017, 173, S4-S10.	1.6	35
18	Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United States. <i>PLoS ONE</i> , 2016, 11, e0167499.	1.1	35

#	ARTICLE	IF	CITATIONS
19	Source of Drugs for Prescription Opioid Analgesic Abusers: A Role for the Internet?. <i>Pain Medicine</i> , 2008, 9, 718-723.	0.9	34
20	Increases in self-reported fentanyl use among a population entering drug treatment: The need for systematic surveillance of illicitly manufactured opioids. <i>Drug and Alcohol Dependence</i> , 2017, 177, 101-103.	1.6	33
21	Relative preferences in the abuse of immediate-release versus extended-release opioids in a sample of treatment-seeking opioid abusers. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 56-62.	0.9	30
22	Determinants of fentanyl and other potent μ opioid agonist misuse in opioid-dependent individuals. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 1057-1063.	0.9	26
23	A tale of 2 ADFs. <i>Pain</i> , 2016, 157, 1232-1238.	2.0	22
24	Psychoactive substance use prior to the development of iatrogenic opioid abuse: A descriptive analysis of treatment-seeking opioid abusers. <i>Addictive Behaviors</i> , 2017, 65, 242-244.	1.7	20
25	Polysubstance use trends and variability among individuals with opioid use disorder in rural versus urban settings. <i>Preventive Medicine</i> , 2021, 152, 106729.	1.6	15
26	Role of key informants and direct patient interviews in epidemiological studies of substance abuse. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 308-312.	0.9	12
27	The impact of opioid use disorder on levels of educational attainment: Perceived benefits and consequences. <i>Drug and Alcohol Dependence</i> , 2020, 206, 107618.	1.6	11
28	Assessment of Chronic Pain Management in the Treatment of Opioid Use Disorder: Gaps in Care and Implications for Treatment Outcomes. <i>Journal of Pain</i> , 2021, 22, 432-439.	0.7	10
29	Oral and non-oral routes of administration among prescription opioid users: Pathways, decision-making and directionality. <i>Addictive Behaviors</i> , 2018, 86, 11-16.	1.7	9
30	Gabapentin prescribed during substance abuse treatment: The perspective of treatment providers. <i>Journal of Substance Abuse Treatment</i> , 2019, 105, 1-4.	1.5	9
31	Understanding multi-pill ingestion of prescription opioids: Prevalence, characteristics, and motivation. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 117-121.	0.9	6
32	Destigmatizing Naloxone: Associations of Perceived Availability on Opioid Use Patterns. <i>Annals of Emergency Medicine</i> , 2021, 77, 134-135.	0.3	5
33	Nonmedical use of gabapentin and opioid agonist medications in treatment-seeking individuals with opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2022, 234, 109400.	1.6	5
34	Shifting Pathways of Stimulant Use Among Individuals With Opioid Use Disorder: A Retrospective Analysis of the Last Thirty Years. <i>Frontiers in Psychiatry</i> , 2021, 12, 786056.	1.3	5
35	Anticipated and unanticipated consequences of abuse deterrent formulations of opioid analgesics. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 205-207.	0.9	4
36	Abuse Deterrent Formulations of Prescription Opioids—Reply. <i>JAMA Psychiatry</i> , 2015, 72, 850.	6.0	3

#	ARTICLE	IF	CITATIONS
37	Opioid Dosage Levels, Concurrent Risk Factors and Self-Perceptions among Chronic Pain, Opioid-Managed Individuals at Elevated Risk for Opioid Overdose. <i>Pharmaceuticals</i> , 2021, 14, 1279.	1.7	2
38	Reply. <i>Pain</i> , 2016, 157, 2875-2876.	2.0	0